Refractory Epilepsy Recruiting Phase 2 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0032649 (Refractory Epilepsy)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03894826Voronistat in Pediatric Patients With Drug Resistant EpilepsyTreatment